---
input_text: 'Decreasing alloimmunization-specific mortality in sickle cell disease
  in the United States: Cost-effectiveness of a shared transfusion resource. Red blood
  cell alloimmunization and consequent delayed hemolytic transfusion reaction (DHTR)
  incidence and mortality in patients with sickle cell disease (SCD) are high. A shared
  transfusion resource has decreased both in other countries, while in the United
  States cost concerns persist. We conducted a Markov cohort simulation of a birth
  cohort of alloimmunized patients with SCD to estimate lifetime DHTR incidence, DHTR-specific
  mortality, quality-adjusted life expectancy (QALE), and costs with the implementation
  of a shared transfusion resource to identify antibody history versus without (i.e.,
  status quo). We conducted our analysis using a lifetime analytic time horizon and
  from a United States health system perspective. Implementation of shared transfusion
  resource projects to decrease cumulative DHTR-specific mortality by 26% for alloimmunized
  patients with SCD in the United States, relative to the status quo. For an average
  patient population of 32 000, this intervention would generate a discounted increment
  of 4000 QALYs at an incremental discounted cost of $0.3 billion, resulting in an
  incremental cost-effectiveness ratio of $75 600/QALY [95% credible interval $70
  200-81 400/QALY]. The results are most sensitive to the baseline lifetime medical
  expenditure of patients with SCD. Alloantibody data exchange is cost-effective in
  100% of 10 000 Monte Carlo simulations. The resource would theoretically need a
  minimum patient population of 1819 patients or cost no more than $5.29 million annually
  to be cost-effective. By reducing DHTR-specific mortality, a shared transfusion
  resource in the United States projects to be a life-saving and cost-effective intervention
  for patients with SCD in the United States.'
raw_completion_output: |-
  primary_disease: sickle cell disease (SCD)

  medical_actions: shared transfusion resource; Markov cohort simulation; alloantibody data exchange

  symptoms: delayed hemolytic transfusion reaction (DHTR)

  chemicals: 

  action_annotation_relationships: shared transfusion resource TREATS delayed hemolytic transfusion reaction (DHTR) IN sickle cell disease (SCD); alloantibody data exchange PREVENTS delayed hemolytic transfusion reaction (DHTR) IN sickle cell disease (SCD)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  alloantibody data exchange PREVENTS delayed hemolytic transfusion reaction (DHTR) IN sickle cell disease (SCD)

  ===

extracted_object:
  primary_disease: MONDO:0007374
  medical_actions:
    - shared transfusion resource
    - Markov cohort simulation
    - alloantibody data exchange
  symptoms:
    - delayed hemolytic transfusion reaction (DHTR)
  action_annotation_relationships:
    - subject: shared transfusion resource
      predicate: TREATES
      object: delayed hemolytic transfusion reaction (DHTR)
      qualifier: MONDO:0007374
    - subject: data exchange
      predicate: PREVENTS
      object: delayed hemolytic transfusion reaction (DHTR)
      qualifier: MONDO:0007374
      subject_extension: aloantibody
named_entities:
  - id: MONDO:0007374
    label: Sickle cell disease (SCD)
  - id: MAXO:0000457
    label: pain management
  - id: HP:0001903
    label: anemia
  - id: CHEBI:44423
    label: hydroxyurea
  - id: CHEBI:18050
    label: L-glutamine
  - id: MAXO:0000058
    label: pharmacotherapy
  - id: HP:0100602
    label: preeclampsia
  - id: HP:0001622
    label: preterm delivery
  - id: HP:0001511
    label: intrauterine growth restriction
  - id: CHEBI:50858
    label: corticosteroids
  - id: HP:0001907
    label: thromboembolism
  - id: MAXO:0000503
    label: Mechanical ventilation
  - id: MONDO:0011382
    label: Sickle Cell Disease
  - id: MAXO:0001001
    label: Gene therapies
  - id: HP:0025322
    label: VOD
  - id: CHEBI:82557
    label: Treosulfan
  - id: MAXO:0000750
    label: conditioning regimen
  - id: MONDO:0007885
    label: Osteonecrosis of the femoral head (AVNFH)
  - id: HP:0012531
    label: Pain
  - id: HP:0000969
    label: Oedema
  - id: MONDO:0018660
    label: hemophilia
  - id: HP:0012532
    label: Chronic pain
  - id: CHEBI:3216
    label: Buprenorphine
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation
  - id: HP:0100543
    label: cognitive dysfunction
  - id: HP:0000739
    label: anxiety
  - id: CHEBI:50131
    label: Decitabine
  - id: CHEBI:29548
    label: Cytidine deaminase (CDA)
  - id: MONDO:0009693
    label: Multiple Myeloma
  - id: CHEBI:145536
    label: Motixafortide
  - id: MAXO:0000601
    label: Dialysis
  - id: HP:0000083
    label: Kidney failure
  - id: MONDO:0100096
    label: COVID-19
  - id: MAXO:0001017
    label: vaccination
  - id: CHEBI:28901
    label: busulfan
  - id: CHEBI:9570
    label: thiotepa
  - id: MAXO:0000952
    label: Hydration therapy
  - id: HP:0006775
    label: Myeloma
  - id: MAXO:0000756
    label: blood transfusions
  - id: MONDO:0005570
    label: Hematologic diseases
  - id: HP:0007760
    label: Sickle cell disease (SCD)
  - id: MAXO:0010203
    label: echocardiography
  - id: CHEBI:31980
    label: Definity
  - id: MAXO:0000149
    label: Hematopoietic stem cell transplantation (HCT)
  - id: HP:0001297
    label: stroke
  - id: CHEBI:6716
    label: Depot medroxyprogesterone acetate
  - id: CHEBI:50114
    label: Estrogen
  - id: CHEBI:59826
    label: Progestin
  - id: MONDO:0005161
    label: Human papillomavirus (HPV)
  - id: MAXO:0000759
    label: HPV vaccination
  - id: MAXO:0000194
    label: opioid therapy
  - id: MAXO:0000882
    label: behavioral modification
  - id: MAXO:0001298
    label: therapy
  - id: MAXO:0010041
    label: skin grafting
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: HP:0002092
    label: Pulmonary hypertension
  - id: MAXO:0000573
    label: use of assisted reproductive technologies (ART)
  - id: HP:0000044
    label: hypogonadotropic hypogonadism (HH)
  - id: HP:0009800
    label: gestational diabetes mellitus
  - id: HP:0011891
    label: post-partum haemorrhage
  - id: HP:0002617
    label: Vasculopathy
  - id: CHEBI:15365
    label: Aspirin
  - id: MAXO:0000068
    label: Transplantation
  - id: HP:0004870
    label: Chronic hemolytic anemia
  - id: CHEBI:27690
    label: Acetazolamide
  - id: MAXO:0001175
    label: liver transplantation
  - id: HP:0000952
    label: jaundice
  - id: MAXO:0000602
    label: Hemodialysis
  - id: MONDO:0002492
    label: Acute kidney injury
  - id: HP:0002240
    label: Hepatomegaly
  - id: HP:0001744
    label: Splenomegaly
  - id: HP:0000790
    label: Hematuria
  - id: HP:0001919
    label: Acute kidney injury
